This can be caused by an outdated browser, graphics card driver issue, or bad weather. Sometimes, just restarting the browser helps. Also, make sure hardware acceleration is enabled in your browser.
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April,[A260880] July,[L47745] and September 2011,[A260880] respectively. It is used to treat metastatic castration-resistant prostate cancer and hormone-sensitive high-risk metastatic prostate cancer.[L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability and absorption.[A3811, A260835]
Synonyms
17-(3-Pyridyl)androsta-5,16-dien-3beta-ol
(3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol
Abiraterone acetate
Abiraterona
Abiraterone
Brand Names
Abiraterone
Zytiga
Mar-abiraterone
Jamp Abiraterone
Abiraterone Accord
Yonsa
Nat-abiraterone
Sandoz Abiraterone
Akeega
Apo-abiraterone
Teva-abiraterone
Abiraterone Krka
Abiraterone Mylan
Apo-abiraterone Film Coated Tablets
Apo-abiraterone Acetate Film Coated Tablets
Reddy-abiraterone
Abiraterone acetate
Prz-abiraterone
PMS-abiraterone
Abiraterone Acetate
Indication
Abiraterone is indicated for the treatment of **metastatic castration-resistant prostate cancer (mCRPC)** in combination with [methylprednisolone] [L40968] or [prednisone].[L40193, L47740, L47745] In Europe and Canada, it is also used in patients with mCRPC who are asymptomatic or mildly symptomatic after the failure of androgen deprivation therapy for whom chemotherapy is not yet clinically indicated.[L47740, L47745] In Europe, it is used in patients whose disease has progressed on or after a docetaxel-based chemotherapy regimen.[L47740] In Canada, it is used in patients who have received prior chemotherapy containing [docetaxel] after the failure of androgen deprivation therapy.[L47745] Abiraterone is indicated in combination with [prednisone] for the treatment of **metastatic high-risk castration-sensitive prostate cancer (CSPC)**.[L40193] In Europe and Canada, it may also be used in combination with [prednisolone] and androgen deprivation therapy in newly diagnosed patients.[L47740, L47745] In Canada and the US, abiraterone is also available in a combination product with [niraparib], which is indicated with [prednisone] for the treatment of adults with deleterious or suspected deleterious BRCA-mutated (BRCAm) mCRPC.[L46896, L47755] In Canada, this combination product is also used with [prednisolone] and is reserved for patients who are asymptomatic or mildly symptomatic, and in whom chemotherapy is not clinically indicated.[L46896]
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
